# Aspen Neuroscience, Inc. (ASPE)

> Source: Nexqual · https://nexqual.com/ASPE · data as of 2026-11-03 21:00 UTC · cite as "Nexqual, Aspen Neuroscience, Inc. (ASPE), nexqual.com/ASPE" · informational, not investment advice.

**Price:** USD 12.29 (-5.75% on the day) · last close of Nov 3, 2026; US market closed, not a live price. Prev close 13.04 · day 12–14.49 · 52w 11.6–14.9 · market cap $357M · NMS

## Key facts
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $38.0M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -17.5% vs S&P 500 +12.9%; 5Y -17.5% vs S&P 500 +72.1%.
- Dividend: ASPE paid no cash dividend in the last five years.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
2 purchases, $38.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-02 | Arch Venture Fund X, L.P. |  | 1,333,333 | $20.0M | 15 | Too little history (no open-market trades in 2023–2025) |
| 2026-11-02 | Arch Venture Partners Xiv, L.P. |  | 1,200,000 | $18.0M | 15 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2026-10-30) | 5Y (from 2026-10-26) |
|---|---|---|
| Total return | -17.5% | -17.5% |
| S&P 500 (SPY) | +12.9% | +72.1% |
| Per year | — | — |
| Volatility (annualized) | 82.4% | 97.8% |
| Max drawdown | -17.5% (Oct 2026→Nov 2026) | -17.5% (Oct 2026→Nov 2026) |

## Dividends
ASPE paid no cash dividend in the last five years.

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 98.89 +1.29% · LGND (Ligand Pharmaceuticals Incorpor) USD 313.52 +2.12% · ORKA (Oruka Therapeutics, Inc.) USD 99.55 +4.32% · IONS (Ionis Pharmaceuticals, Inc.) USD 40.42 -1.99% · AXSM (Axsome Therapeutics, Inc.) USD 139.61 +2.65% · ABVX (Abivax SA) USD 88.71 +4.48%

## More
Full page: https://nexqual.com/ASPE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-03 | Schedule 13G | Qatar Investment Authority: 6.7% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/2124080/000144144926000011/0001441449-26-000011-index.htm |
| 2026-11-02 | 8-K | Bylaws or fiscal-year change; Other material event — “On November 2, 2026, the Company completed the IPO of 9,375,000 shares of the Company's common stock, par value $0.0001 per share, at a price to the public of $15.00 per share. The gross proceeds to the Company from the IPO were approximately $140.6 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.” | https://www.sec.gov/Archives/edgar/data/2124080/000119312526443805/0001193125-26-443805-index.htm |
| 2026-10-26 | S-1/A | Registration of new shares | https://www.sec.gov/Archives/edgar/data/2124080/000119312526431023/0001193125-26-431023-index.htm |
| 2026-10-22 | S-1/A | Registration of new shares | https://www.sec.gov/Archives/edgar/data/2124080/000119312526428300/0001193125-26-428300-index.htm |
| 2026-10-09 | S-1 | Registration of new shares | https://www.sec.gov/Archives/edgar/data/2124080/000119312526419104/0001193125-26-419104-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.